Drugs / MBX-2982
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04432090 | Apr 2021 → Aug 2023 | type 1 diabetes mellitus | AdventHealth Translational Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01035879 | Dec 2009 → Aug 2010 | diabetes mellitus | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBX-2982 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04432090 ↗ |
| Action | Activate | “Glucose-dependent insulinotropic receptor agonist” CHEMBL3260505 ↗ |
| Modality | Small molecule | — CHEMBL3260505 ↗ |
| Route | Oral | “a pill that contains the study medication (MBX-2982)” NCT04432090 ↗ |
| Target | GPR119 | “Glucose-dependent insulinotropic receptor agonist” CHEMBL3260505 ↗ |